Tafamidis Dosage

Medically reviewed by Drugs.com. Last updated on Sep 6, 2024.

Usual Adult Dose for Amyloidogenic Transthyretin Amyloidosis

Tafamidis meglumine (Vyndaqel): 80 mg orally once a day (Four 20 mg capsules/day)
OR
Tafamidis (Vyndamax): 61 mg orally once a day (One 61 mg capsule/day)

Comments:

• Tafamidis and tafamidis meglumine products are not substitutable on a per mg basis.

Use: For the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.

Renal Dose Adjustments

No adjustment recommended

Liver Dose Adjustments

Mild to moderate liver dysfunction: No adjustment recommended
Severe liver dysfunction: Use with caution

Precautions

CONTRAINDICATIONS: None

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

• Tafamidis and tafamidis meglumine are not interchangeable on a per mg basis.
• Take orally once a day with or without food; the capsules should be swallowed whole, not crushed or chewed.

Missed Dose: If a dose is missed, take the dose as soon as remembered or skip the missed dose and take the next dose at the regularly scheduled time; do not double the dose

General:

• For patients with wild type or hereditary transthyretin-mediated amyloidosis, there is an international disease registry called the Transthyretin Amyloidosis Outcome Survey (THAOS), designed to assess disease progression, genotype/phenotype relationships, and the impact of interventions, including this drug, on disease progression; participation is voluntary, and may involve long-term follow-up. For information regarding the registry, visit www.thaos.net.

Patient advice:

• Patients should be instructed to read the US FDA-approved patient labeling (Patient Information).
• Patients should be advised of the availability of the Transthyretin Amyloidosis Outcome Survey (THAOS) international voluntary registry designed to assess disease progression, genotype/phenotype relationships, and the impact of interventions.
• Advise pregnant women and females of reproductive potential of the potential risk to a fetus and to inform of a known or suspected pregnancy; pregnancy should be reported to Pfizer reporting line at 1-800-438-1985.
• Advise females not to breastfeed during treatment.

Frequently asked questions

• How long does it take Vyndamax to work?
• How long does it take for Vyndaqel to start working?

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer